Moffitt Cancer Center study shows improved response rates in myelodysplastic syndromes patients treated with lenalidomide and epoetin alpha

(H. Lee Moffitt Cancer Center & Research Institute) Patients with myelodysplastic syndromes (MDS) suffer from a reduction in the number of different types of blood cells, including red blood cells leading to the development of anemia. Many patients with lower-risk MDS benefit from treatment with recombinant-erythropoietin (rHuEPO), which stimulates blood cell production. However, patients who become refractory to rHuEPO have few effective treatment options.